Your browser doesn't support javascript.
loading
Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.
Khor, Chiea Chuen; Winter, Stefan; Sutiman, Natalia; Mürdter, Thomas E; Chen, Sylvia; Lim, Joanne Siok Liu; Li, Zheng; Li, Jingmei; Sim, Kar Seng; Ganchev, Boian; Eccles, Diana; Eccles, Bryony; Tapper, William; Zgheib, Nathalie K; Tfayli, Arafat; Ng, Raymond Chee Hui; Yap, Yoon Sim; Lim, Elaine; Wong, Mabel; Wong, Nan Soon; Ang, Peter Cher Siang; Dent, Rebecca; Tremmel, Roman; Klein, Kathrin; Schaeffeler, Elke; Zhou, Yitian; Lauschke, Volker M; Eichelbaum, Michel; Schwab, Matthias; Brauch, Hiltrud B; Chowbay, Balram; Schroth, Werner.
Afiliação
  • Khor CC; Division of Human Genetics, Genome Institute of Singapore, Singapore, Singapore.
  • Winter S; Singapore Eye Research Institute, Singapore, Singapore.
  • Sutiman N; Clinical Pharmacology, SingHealth, Singapore, Singapore.
  • Mürdter TE; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Chen S; University Tübingen, Tübingen, Germany.
  • Lim JSL; Clinical Pharmacology Laboratory, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore.
  • Li Z; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Li J; University Tübingen, Tübingen, Germany.
  • Sim KS; Clinical Pharmacology Laboratory, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore.
  • Ganchev B; Clinical Pharmacology Laboratory, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore.
  • Eccles D; Division of Human Genetics, Genome Institute of Singapore, Singapore, Singapore.
  • Eccles B; Division of Human Genetics, Genome Institute of Singapore, Singapore, Singapore.
  • Tapper W; Division of Human Genetics, Genome Institute of Singapore, Singapore, Singapore.
  • Zgheib NK; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Tfayli A; University Tübingen, Tübingen, Germany.
  • Ng RCH; Faculty of Medicine, Cancer Sciences Academic Unit and University of Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Yap YS; University Hospital Southampton National Health Service Foundation Trust, Southampton, UK.
  • Lim E; Faculty of Medicine, Cancer Sciences Academic Unit and University of Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Wong M; University Hospital Southampton National Health Service Foundation Trust, Southampton, UK.
  • Wong NS; Faculty of Medicine, Cancer Sciences Academic Unit and University of Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Ang PCS; University Hospital Southampton National Health Service Foundation Trust, Southampton, UK.
  • Dent R; Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
  • Tremmel R; Hematology-Oncology Division, Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
  • Klein K; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Schaeffeler E; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Zhou Y; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Lauschke VM; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Eichelbaum M; OncoCare Cancer Centre, Mount Elizabeth Novena Medical Centre, Singapore, Singapore.
  • Schwab M; OncoCare Cancer Centre, Mount Elizabeth Novena Medical Centre, Singapore, Singapore.
  • Brauch HB; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Chowbay B; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Schroth W; University Tübingen, Tübingen, Germany.
Clin Pharmacol Ther ; 113(3): 712-723, 2023 03.
Article em En | MEDLINE | ID: mdl-36629403
ABSTRACT
The therapeutic efficacy of tamoxifen is predominantly mediated by its active metabolites 4-hydroxy-tamoxifen and endoxifen, whose formation is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6). Yet, known CYP2D6 polymorphisms only partially determine metabolite concentrations in vivo. We performed the first cross-ancestry genome-wide association study with well-characterized patients of European, Middle-Eastern, and Asian descent (n = 497) to identify genetic factors impacting active and parent metabolite formation. Genome-wide significant variants were functionally evaluated in an independent liver cohort (n = 149) and in silico. Metabolite prediction models were validated in two independent European breast cancer cohorts (n = 287, n = 189). Within a single 1-megabase (Mb) region of chromosome 22q13 encompassing the CYP2D6 gene, 589 variants were significantly associated with tamoxifen metabolite concentrations, particularly endoxifen and metabolic ratio (MR) endoxifen/N-desmethyltamoxifen (minimal P = 5.4E-35 and 2.5E-65, respectively). Previously suggested other loci were not confirmed. Functional analyses revealed 66% of associated, mostly intergenic variants to be significantly correlated with hepatic CYP2D6 activity or expression (ρ = 0.35 to -0.52), and six hotspot regions in the extended 22q13 locus impacting gene regulatory function. Machine learning models based on hotspot variants (n = 12) plus CYP2D6 activity score (AS) increased the explained variability (~ 9%) compared with AS alone, explaining up to 49% (median R2 ) and 72% of the variability in endoxifen and MR endoxifen/N-desmethyltamoxifen, respectively. Our findings suggest that the extended CYP2D6 locus at 22q13 is the principal genetic determinant of endoxifen plasma concentration. Long-distance haplotypes connecting CYP2D6 with adjacent regulatory sites and nongenetic factors may account for the unexplained portion of variability.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Citocromo P-450 CYP2D6 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Citocromo P-450 CYP2D6 Idioma: En Ano de publicação: 2023 Tipo de documento: Article